# Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

> **NCT01078441** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 2 (actual)

## Conditions studied

- Refractory Multiple Myeloma

## Interventions

- **DRUG:** liposomal doxorubicin
- **DRUG:** bortezomib
- **DRUG:** dexamethasone
- **DRUG:** cyclophosphamide

## Key facts

- **NCT ID:** NCT01078441
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-09
- **Primary completion:** 2014-02
- **Final completion:** 2014-03
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** The study was closed early due to weak accrual on June 26, 2012.
- **Last updated:** 2015-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01078441

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01078441, "Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01078441. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*